IRIS
PERSONENI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 191
NA - Nord America 91
EU - Europa 20
SA - Sud America 2
AF - Africa 1
Totale 305
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 177
US - Stati Uniti d'America 84
MX - Messico 6
GB - Regno Unito 4
HK - Hong Kong 4
IT - Italia 4
DE - Germania 3
CN - Cina 2
FR - Francia 2
JP - Giappone 2
PL - Polonia 2
AE - Emirati Arabi Uniti 1
BR - Brasile 1
CA - Canada 1
CH - Svizzera 1
CO - Colombia 1
ES - Italia 1
IN - India 1
IQ - Iraq 1
LT - Lituania 1
PK - Pakistan 1
RS - Serbia 1
RU - Federazione Russa 1
UZ - Uzbekistan 1
VN - Vietnam 1
ZA - Sudafrica 1
Totale 305
Salva come PNG Salva come JPEG
Città #
Singapore 112
Ashburn 14
Buffalo 11
Council Bluffs 10
Los Angeles 9
Denver 4
Hong Kong 4
Querétaro 4
Boardman 3
Milan 3
Atlanta 2
Boston 2
Dallas 2
London 2
Mexico City 2
Munich 2
New York 2
Tokyo 2
Warsaw 2
Beijing 1
Belgrade 1
Bismarck 1
Charleston 1
Chennai 1
Da Nang 1
Frankfurt am Main 1
Harrisburg 1
Honolulu 1
Johannesburg 1
La Rochelle 1
Lahore 1
Makhachkala 1
Manchester 1
Miami 1
Montreal 1
Newark 1
Orem 1
Paris 1
Poplar 1
São Paulo 1
Tashkent 1
Yumbo 1
Totale 215
Salva come PNG Salva come JPEG
Nome #
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study 13
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 12
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 9
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 8
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 8
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 7
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 7
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 7
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 7
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 7
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 7
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer : the VanGogh study 6
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer 6
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 6
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 6
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 6
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 6
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 6
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma 6
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 6
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 6
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 6
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 6
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial 6
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 5
Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer single institution experience 5
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 5
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 5
Targeted agents for second-line treatment of advanced hepatocellular carcinoma 5
Which choice of therapy when many are available? - Current systemic therapies for advanced hepatocellular carcinoma 5
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 5
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 4
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 4
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study 4
Regorafenib for the treatment of unresectable hepatocellular carcinoma 4
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 4
COVID-19 and liver cancer clinical trials: not everything is lost 4
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 4
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 4
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 4
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment 4
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors 4
Rationale for immunotherapy combination strategies in unresectable hepatocellular carcinoma 4
Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications 4
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 4
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients 4
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 4
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 4
Biomarkers in Hepatocellular Carcinoma-Letter 4
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression : a Phase II Study 4
Cabozantinib for the treatment of hepatocellular carcinoma 4
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 3
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 3
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study 3
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 3
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 3
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice 3
Tivantinib for second-line treatment of advanced hepatocellular carcinoma : a randomised, placebo-controlled phase 2 study 3
Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater! 3
Tivantinib : a new promising mesenchymal–epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 3
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma 3
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 3
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 2
Standardisation of EGFR FISH in colorectal cancer: Results of an international interlaboratory reproducibility ring study 2
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy 2
Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes 2
Fatal Infusion Reaction to Cetuximab : The Need for Predictive Risk Factors and Safer Patient Selection 2
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 2
Shaping the landscape of immune oncology in hepatocellular carcinoma 2
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 2
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study 2
Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial 2
OncoAlert round table discussions: The global COVID-19 experience 2
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date 2
SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS 2
Biomarkers in hepatocellular carcinoma - Letter 2
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 2
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 2
Shaping the landscape of immune oncology in hepatocellular carcinoma 2
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 2
Reply to Y. Pointreau et al 2
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma 2
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 2
Outcome prediction to erlotinib in gastroesophageal adenocarcinomas : can we improve epidermal growth factor receptor and phospho-AKT testing? 2
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study 2
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) 2
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 2
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 2
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 2
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 2
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 2
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 2
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 2
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery : a retrospective study 2
Response prediction to EGFR-targeted therapies in colorectal cancer 2
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 2
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 2
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 2
NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable Hepatocellular carcinoma 2
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 2
Totale 394
Salva come PNG Salva come JPEG
Categoria #
all - tutte 4.354
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.354
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2025/2026468 0 0 0 0 313 155 0 0 0 0 0 0
Totale 468